News | February 03, 2024
Thyrocare Technologies posts Q3 FY24 consolidated PAT at Rs. 15.35 Cr
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
Furthering cell therapy ambition across oncology and autoimmune diseases
Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
The company has reported total income of Rs. 135.87 crores during the period ended June 30, 2023
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
Subscribe To Our Newsletter & Stay Updated
